Psychedelics Archives - Page 48 of 68

2 minute read

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism’s Genetic Cause Receives Approval

December 27, 1:47 PM

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic mushrooms therapy for this condition.

KONEF

2 minute read

This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage

By Lara Goldstein

December 22, 4:49 PM

Short-acting psychedelics biotech company Small Pharma Inc.

DMTTF

4 minute read

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK’s Research Support And More

By Lara Goldstein

December 19, 9:23 PM

Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

AWKNF

2 minute read

Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing

By Lara Goldstein

December 19, 1:47 PM

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).

DMTTF

2 minute read

Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment

By Lara Goldstein

December 19, 11:28 AM

Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to CEO Adi Zuloff-Shani.

CMND

2 minute read

FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder

By Lara Goldstein

December 16, 6:03 PM

After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S.

EHVVF

2 minute read

Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans

By Lara Goldstein

December 16, 5:54 PM

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed:

AWKNF

2 minute read

Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials

By Lara Goldstein

December 16, 5:46 PM

Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).

PSYGF

2 minute read

FDA OKs Ketamine For Treating Organ Transplant Injuries With ‘Orphan Drug’ Status

By Lara Goldstein

December 15, 3:12 PM

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.

PHRRF